TAKEDA PHARMACEUTICALS AMERICA, INC. drugs
32 results
Adzynma (apadamtase alfa)
(Apadamtase Alfa)TAKEDA PHARMACEUTICALS AMERICA, INC.
Usage: ADZYNMA (ADAMTS13, recombinant-krhn) is indicated for prophylactic or on-demand enzyme replacement therapy in adults and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).
Alunbrig (brigatinib)
(brigatinib)Takeda Pharmaceuticals America, Inc.
Usage: ALUNBRIG is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as confirmed by an FDA-approved test.
Carbatrol (carbamazepine)
(carbamazepine)Takeda Pharmaceuticals America, Inc.
Usage: Carbatrol is indicated as an anticonvulsant for treating partial seizures (with complex symptoms), generalized tonic-clonic seizures, and mixed seizure patterns in epilepsy. Additionally, it is used to manage pain associated with true trigeminal neuralgia and has shown benefits in glossopharyngeal neuralgia. Not intended for trivial pain relief.
Ceprotin (protein c concentrate human)
(Protein C Concentrate Human)Takeda Pharmaceuticals America, Inc.
Usage: CEPROTIN® is indicated for the prevention and treatment of venous thrombosis and purpura fulminans in neonates, pediatric, and adult patients with severe congenital Protein C deficiency.
Cinryze (human c1-esterase inhibitor)
(HUMAN C1-ESTERASE INHIBITOR)Takeda Pharmaceuticals America, Inc.
Usage: CINRYZE is indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (ages 6 and older) with Hereditary Angioedema (HAE).
Cuvitru (immune globulin subcutaneous (human))
(Immune Globulin Subcutaneous (Human))Takeda Pharmaceuticals America, Inc.
Usage: CUVITRU is indicated for replacement therapy in primary humoral immunodeficiency in patients aged two years and older, including conditions such as common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Elaprase (idursulfase)
(idursulfase)Takeda Pharmaceuticals America, Inc.
Usage: ELAPRASE is indicated for patients with Hunter syndrome (MPS II), improving walking capacity in those aged 5 and older. For patients 16 months to 5 years, it has shown reduced spleen volume but lacks data on clinical outcomes. Safety is unestablished for children under 16 months.
Entyvio (vedolizumab)
(vedolizumab)Takeda Pharmaceuticals America, Inc.
Usage: ENTYVIO is indicated for adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).
Eohilia (budesonide)
(Budesonide)TAKEDA PHARMACEUTICALS AMERICA, INC.
Usage: EOHILIA™ is indicated for 12 weeks of treatment in adults and pediatric patients aged 11 and older with eosinophilic esophagitis (EoE). It is not proven safe or effective for EoE treatment beyond 12 weeks.
Firazyr (icatibant acetate)
(icatibant acetate)Takeda Pharmaceuticals America, Inc.
Usage: FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years and older.